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The b-defensins are a class of small, cationic pro-
teins first recognized as antimicrobial components
of the innate and adaptive immune system. More
recently, one of the major b-defensins produced in
skin, b-defensin 3, has been discovered to function
as a melanocortin receptor ligand in vivo and
in vitro, but its biophysical and pharmacological
basis of action has been enigmatic. Here, we report
functional and biochemical studies focused on
human b-defensin 3 (HBD3) and melanocortin recep-
tors 1 and 4. Genetic and pharmacologic studies
indicate that HBD3 acts as a neutral melanocortin
receptor antagonist capable of blocking the action
of either stimulatory agonists such as a-melanocyte
stimulating hormone or inhibitory inverse agonists
such as Agouti signaling protein (ASIP) and Agouti-
related protein (AGRP). A comprehensive structure-
function analysis demonstrates that two patches of
positively charged residues, located on opposite
poles of HBD3 and spatially organized by the
compact b-defensin fold, are primarily responsible
for high-affinity binding to melanocortin receptors.
These findings identify a distinct mode of melano-
cortin receptor-ligand interactions based primarily
on electrostatic complementarity, with implications
for designing ligands that target melanocortin and
potentially other seven transmembrane receptors.
INTRODUCTION
b-defensins are a rapidly evolving family of small secreted pro-
teins thought to mediate a response to diverse and changing
environmental stress (Pazgier et al., 2006). Named by analogy
to the a-defensins, which are key antimicrobial components of
neutrophil granules, mammalian b-defensins are expressed
primarily in epithelial tissues, often inducible upon exposure to
proinflammatory agents (Lehrer, 2004). Initially recognized for
their potential as ‘‘endogenous antibiotics,’’ some b-defensins
can act as ligands for G protein-coupled receptors, including
those of the chemokine and melanocortin systems (Candille784 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 Elsevieret al., 2007; Ro¨hrl et al., 2010; Yang et al., 2000a; Yang et al.,
1999).
We became interested in b-defensins as seven transmem-
brane receptor ligands based on the observation that a common
Mendelian trait in domestic dogs, dominant inheritance of a
black coat color, was caused by mutation of the b-defensin
gene canine b-defensin 103 (CBD103) (Candille et al., 2007). In
laboratory mice andmany other mammals, dominant inheritance
of a black coat color is caused by mutations that constitutively
activate the melanocortin 1 receptor (Mc1r) (Barsh et al., 2000).
Melanocortin receptors are named for their ability to stimulate
cAMP production in response to small peptide agonists such
as a-melanocyte stimulating hormone (a-MSH). In vivo, how-
ever, the Mc1r and Mc4r exhibit high levels of basal activity in
the absence of agonists and are often regulated by production
of the endogenous inverse agonists Agouti signaling protein
(ASIP) and Agouti-related protein (AGRP), respectively, which
elicit biological effects through their ability to depress cAMP
levels by inhibiting melanocortin receptor activity (Ollmann and
Barsh, 1999).
Our earlier studies suggested that CBD103 acted as a ligand
for the MC1R, because CBD103 and its human ortholog, human
b-defensin 3 (HBD3), bound specifically to the MC1R expressed
in cultured cells, and because transgenic mice that overex-
pressed CBD103 exhibited dominant inheritance of a black
coat color. Although overexpression of CBD103 mimics the
coat color effects of a-MSH in vivo, CBD103 did not stimulate
cAMP production in vitro, which suggested that CBD103
blocked the ability of ASIP to bind to the MC1R, thereby main-
taining high basal levels of MC1R signaling. In these initial
studies, HBD3 and CBD103 also bound to the MC4R, a brain
melanocortin receptor that controls feeding and body weight,
which suggested an additional molecular route for these and
possibly other b-defensins to modulate a variety of physiologic
processes.
The relationship between CBD103 and pigmentation in dogs
and in transgenic mice has led to interest in the possibility that
HBD3 might affect MC1R signaling in humans; however, recent
studies have yielded somewhat conflicting results. In cultured
human melanocytes, Swope et al. (2012) reported that HBD3
had no effect on cAMP levels but blocked the ability of a-MSH
to stimulate cAMP accumulation, leading these investigators to
describe HBD3 as an MC1R antagonist. By contrast, Beaumont
et al. (2012) observed that HBD3 promoted cAMP accumulation
and MAP kinase activation in human embryonic kidney (HEK)Ltd All rights reserved
Figure 1. Structure and Sequence of HBD3
(A and B) HBD3 structure (A) is represented by ribbon diagram with helices in
red and b strands in purple. Positively charged residue side chains are
numbered and displayed in blue. The three disulfide bridges are displayed in
yellow. (B) HBD3 structure is represented by ribbon diagram and displays the
solvent-exposed surface area colored by side chain charge. Patches of
positively charged residues are found on opposite sides of the peptide
structure. These were deemed patch 1, the grouping on the top of the structure
as it is oriented here, and patch 2 on the bottom of the structure grouped near
the C terminus.
(C) The primary sequence of mature HBD3 and CBD103 (residues 23–67) with
the native disulfide connectivity shown. See also Figure S3 and Table S1.
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Binding Determinants of HBD3 and MC Receptorscells transfected with theMC1R and described HBD3 as a partial
MC1R agonist.
To better understand the molecular basis for b-defensin
action, we have now carried out a series of additional genetic
and pharmacologic studies to probe the actions of HBD3 in vivo
and to characterize the structural determinants of HBD3 that are
required for melanocortin receptor binding. Despite little
sequence homology among members of the b-defensin family,
those that have been structurally characterized all share a
remarkably similar secondary and tertiary architecture (Bauer
et al., 2001; Hoover et al., 2001; Hoover et al., 2000; Sawai
et al., 2001; Schibli et al., 2002). Common features include three
antiparallel b-strands stabilized into a compact fold by three
conserved disulfide bridges in the topology CysI–CysV, CysII–
CysIV, and CysIII–CysVI that distinguish them from other classes
of defensins (Pazgier et al., 2006) (Figure 1A). Generally they
possess a high net-positive charge and are amphiphilic, features
that contribute to their ability to disrupt microbial membraneChemistry & Biology 20,structure (Klu¨ver et al., 2005). However, b-defensins share little
sequence or structural similarities with all previously known
melanocortin ligands.
As described below, we find that HBD3 behaves as a neutral
antagonist at both theMC1R and theMC4R, blocking the effects
of the inverse agonists ASIP and AGRP, respectively. Our struc-
tural studies indicate that receptor binding is mediated by two
solvent-exposed patches of positively charged residues located
on opposite poles of HBD3. This binding interaction appears to
be distinct from other known melanocortin ligand-receptor inter-
actions and allows HBD3 to achieve high affinity-binding through
its diffuse charged surface and electrostatic characteristics.
RESULTS
b-Defensin Relationships and Nomenclature
Our original studies on b-defensins were based on dog coat
color genetics and used both dog and human peptides. For
the genetic work described below, we made use of mice that
carry a CBD103 transgene (a dog cDNA) controlled by a strong,
widely expressed promoter (Candille et al., 2007). However, for
the structure-function work that follows, we have focused exclu-
sively on the human peptide. There is an orthologous relationship
(suggesting conservation of function) between theCBD103 (dog)
and DEFB103 (human) genes, whose protein products are
referred to as CBD103 and HBD3, respectively (Patil et al.,
2005). The mature peptides (after signal sequence cleavage)
are both 45 residues in length, and there are 7 conservative sub-
stitutions between the dog and human peptides (Figure 1C); as
shown below, HBD3 has nearly identical properties to CBD103
(Candille et al., 2007) in terms of binding to theMC1R andMC4R.
b-Defensin Pharmacology and Genetic Interaction with
Melanocortin Systems
Even thoughCBD103mimics the effect ofMC1Ragonists in vivo,
neither CBD103 (Candille et al., 2007) nor HBD3 (Figure S1A,
available online) stimulate or reduce cAMP levels in melan-a
cells, which represent a physiologically relevant and sensitive
system for measuring MC1R activation. We also examined
b-arrestin recruitment by the MC1R, which provides a sensitive
test for receptor activation via an alternative effector (Ferguson
et al., 1996; Lohse et al., 1990). Melanotan-II, a synthetic mela-
nocortin agonist peptide, promoted robust MC1R/ b-arrestin
coupling (EC50 = 5.4 3 10
10 M), but there was no response to
CBD103 or to ASIP in this assay (Figure S1B).
To investigate the interaction between CBD103 and Mc1r
signaling in vivo, we extended earlier work in which Tg.CBD103
was shown to cause a black coat color in mice whose Asip
genotype is A/a (Candille et al., 2007). The A allele is character-
ized by transient expression of Asip during the hair growth cycle,
which, via transient inhibition ofMc1r signaling, gives rise to hairs
that contain a band of yellow pigment on an otherwise black
background. In mice carrying the Ay allele, Asip is expressed
throughout the entire hair growth cycle, giving rise to animals
that are entirely yellow; in this background (Ay/a), we observed
that Tg.CBD103 also caused a black coat (Figure 2A; Table 1).
By contrast, in mice carrying an Mc1r loss-of-function mutation
that, like Ay, gives rise to mice that are entirely yellow,
Tg.CBD103 has no effect on coat color (Figure 2B; Table 1).784–795, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 785
Figure 2. Transgenic Mouse Models and ICV Experiments
(A) Ay/a background mice with and without CBD103 transgene expression.
(B) Mc1r/ background mice with and without CBD103 transgene expression.
(C) Effects of HBD3 ICV injection on food intake and body weight change over time during refeeding experiments.
(D) Effects of ICV injection of AgRP and HBD3 on change in body weight over time during free feeding. Each data point is represented as the mean of 6–7
animals ±SEM. (Note: all mice shown are less than eight weeks of age.)
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Binding Determinants of HBD3 and MC ReceptorsThus, CBD103 is genetically downstream of Asip but upstream
of the Mc1r.
The results described above could also be explained if
Tg.CBD103 caused increased expression of Proopiomelano-
cortin (Pomc), the precursor to a-MSH. Therefore, we asked
whether the coat color effects of Tg.CBD103 were dependent
on Pomc. In our genetic background (a mixture of three inbred
strains—129, C57BL/6J, and FVB/N), A/A mice homozygous
for a Pomc loss-of-function allele have banded hairs, and the
addition of Tg.CBD103 converts the coat color to black (Table 1).
Thus, the effects of CBD103 on coat color depend on the
Mc1r but not on endogenous melanocortins, which pro-
vides strong genetic support for the conclusion that the
pigmentary effects of CBD103 result from a direct interaction
with the Mc1r, despite the inability of CBD103 to modulate
receptor coupling.
Effect of HBD3 on CNS Melanocortin Signaling
A shift in the balance between black and yellow pigment syn-
thesis provides a very sensitive readout for melanocortin activity.786 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 ElsevierHowever, a disadvantage of the pigmentary system is that hair
follicle melanocytes—the Mc1r-expressing cells engaged by
Asip and by CBD103—do not maintain a pigment type-switching
response in culture, and the tissue compartment in which those
cells reside is relatively inaccessible, which makes pharmaco-
logic studies difficult.
As an alternative approach to study the pharmacology of
b-defensin action in vivo, we studied the feeding behavior
of rats in response to intracerebroventricular (ICV) injection of
melanocortin receptor ligands. Previous studies have estab-
lished that a-MSH and AgRP are potent central nervous system
(CNS) modulators of energy balance when injected ICV, causing
inhibition and stimulation of feeding, respectively, mediated
largely through the Mc4r. In pilot studies of free-feeding rats
implanted with ICV cannulas, we observed that injection of
0.01–2 nmol of HBD3 had no effect on behavior or food intake;
we chose a dose of 7 mg (1.2 nmol) for subsequent studies
because AgRP injected ICV stimulates feeding at doses of
0.01–0.2 nmol, and the affinity of HBD3 for Mc4r is 50- to
100-fold less than AgRP (see below).Ltd All rights reserved
Table 1. Epistasis of CBD103 Transgene and Pigment-Type
Switching Genes
Genotype
Coat ColorMelanocortin System CBD103 Transgene
a/a; Mc1r/; Pomc+/+ +/+ Yellow
a/a; Mc1r/; Pomc+/+ Tg/+ Yellow
Ay/a; Mc1r+/+; Pomc+/+ +/+ Yellow
Ay/a; Mc1r+/+; Pomc+/+ Tg/+ Black
A/A; Mc1r+/+; Pomc/ +/+ Agouti
A/A; Mc1r+/+; Pomc/ Tg/+ Black
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Binding Determinants of HBD3 and MC ReceptorsWe first tested the effects of HBD3 on ‘‘refeeding’’ after 24 hr
of food deprivation, which provides a sensitive assay for alter-
ations in endogenous Mc4r signaling. Animals (n = 6–7/group)
were injected either with water or with HBD3 at the onset of
fasting and then allowed free access to food during subsequent
monitoring. Under these conditions, when food is restored, rats
exhibit a compensatory hyperphagia and recover most of their
prefasting body weight by 24 hr; HBD3 treatment had a small
but significant inhibitory effect on both the food intake and
body weight response (Figure 2C; p = 0.0065 for food intake,
p = 0.023 for body weight).
We then tested whether HBD3 would affect the response to a
submaximal dose (0.01 nmol) of exogenous AgRP in free-feeding
animals. In this paradigm, ICV injection of AgRP has no detect-
able effect on food intake in the first 24 hr (data not shown) but
nevertheless elicits a positive and persistent energy balance
response with increased weight gain (Figure 2D). ICV injection
of HBD3 1 hr before AgRP completely blocked this response
(p = 0.0009) such that animals injected with Vehicle + Vehicle
exhibited a body weight response that was not significantly
different (p = 0.56) from animals injected with AgRP+HBD3 (Fig-
ure 2D). In summary, HBD3 has a small but significant effect on
the physiologic response to endogenous AgRP (Figure 2C) and a
dramatic effect on the pharmacologic response to administered
AgRP (Figure 2D).
Structure-Function Analysis of HBD3 Binding
to Melanocortin Receptors
Taken together, the results described above suggest that HBD3
(or CBD103) can act as a neutral antagonist at both theMc1r and
Mc4r, blocking the ability of either the agonist a-MSH or the
endogenous inverse agonists Asip and AgRP to signal through
their cognate receptors. Because of the distinct ligand pro-
perties of HBD3, we sought to further characterize the molecular
determinants responsible for its interaction with melanocortin
receptors.
Effects of Mutations That Impair HBD3 Charged
and Aromatic Residues
Previously characterized melanocortin ligands share a similar
binding motif comprised of cationic and aromatic residues,
including the RFF sequence in inverse agonists and the HFRW
sequence in agonists (Bolin et al., 1999; Hruby et al., 1987;
Kiefer et al., 1998; Tota et al., 1999). Substitution of any of these
residues individually or in groups greatly reduces melanocortin
receptor affinity and function; for example, the RFF / AFF
mutation in Asip reduces MC1R affinity by over 760-fold (Ki =Chemistry & Biology 20,2.6 nM/ Ki > 1900nM) (Kiefer et al., 1998). The N-terminal helix
of HBD3 has a single linear sequence of positively charged and
aromatic residues—K30Y31Y32—similar to RFF motif in the
inverse agonists. However, we found that substituting either
K30 or Y32 with alanine residues had little overall effect on bind-
ing, reducing MC1R/ MC4R affinity 1.5-fold (Table 2). We also
systematically replaced all of the lysines and arginines present in
the HBD3 sequence with alanine or glutamine in a series of
single, double, and multiple point mutations. Alanine was
primarily used for single and double residue substitutions,
whereas glutamine was utilized for multiple substitutions to
better reflect side chain structure and bulk while maintaining
peptide solubility. Mutating any single or group of two or three
charged residues had little effect on receptor binding; these
peptide variants bound to MC1R and MC4R with affinities
comparable to HBD3, exhibiting remarkable resilience to modi-
fication (Figure 3; Table 2).
The Effects of Mutations That Impair HBD3 Tertiary
Structure
A hallmark of the b-defensins is their conserved and compact
secondary and tertiary structure (Figure 1), stabilized by disulfide
bonding. Reduction of the disulfides can significantly com-
promise b-defensin action; for example, in the case where
b-defensin 3 suppresses proinflammatory pathways (Semple
et al., 2011). We synthesized a series of peptides in which disul-
fide bonding is disrupted by replacing some or all of the six
cysteine residues with serine residues (Table 2). Surprisingly,
elimination of all disulfide bonds from HBD3 (HBD3-Cys /
Ser) reduced but did not abolish HBD3 binding to MC1R or
MC4R, with a 7-fold reduction at MC1R (Ki = 42 nM to Ki =
297 nM) and a 4-fold reduction at MC4R (Ki = 110 nM to Ki =
436 nM) relative to HBD3 (Figure 3; Table 2). Peptides in which
two of the three disulfide bonds were eliminated behaved
similarly to the complete HBD3-Cys / Ser peptide (Table 2).
We considered whether the HBD3-Cys/ Ser mutant might still
fold normally; however, natural abundance 15N HSQC on
HBD3-Cys/ Ser exhibited very little amide proton dispersion
compared to the fully folded native HBD3 spectra (Figure S2).
Thus, like other b-defensins for which disulfide bonding is critical
for stabilizing the defensin fold, HBD3-Cys/ Ser has little or no
regular structure (Bauer et al., 2001).
In addition to disulfide bonding, several other residues that
are well conserved throughout the b-defensin family may also
play a role in stabilizing the compact fold of b-defensins. Gluta-
mate 49, for example, is thought to form an intramolecular salt
bridge with R39 that both stabilizes the fold and assists dimer
formation (Boniotto et al., 2003; Schibli et al., 2002). We syn-
thesized an HBD3 E49A variant and observed a 2- to 3-fold
reduction in binding affinity at MC1R and MC4R (Ki = 146 nM
and 222 nM, respectively) (Table 2). This reduction in affinity
is the largest observed for any of the single point mutants
and is consistent with the conclusion that the compact fold of
the protein facilitates but is not absolutely required for receptor
binding. As controls, we designed three additional HBD3
peptides in which large regions were eliminated and in which
all cysteine residues in these truncated variants were
substituted with serines. None of these peptides (N-term Trun-
cate, C-term Truncate, Middle Truncate; Table 2) exhibited
significant receptor binding.784–795, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 787
Table 2. Sequence, Charge, and Binding Constants Ki for Synthetic Human b-Defensin 3 Peptides
Peptide Mutant Sequence Charge hMc1ra Ki (nM) hMc4r
a Ki (nM)
Native HBD3 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK +11 42 110
Cys/ Serb GIINTLQKYYSRVRGGRSAVLSSLPKEEQIGKSSTRGRKSSRRKK +11 297 436
CysI–V GIINTLQKYYCRVRGGRSAVLSSLPKEEQIGKSSTRGRKCSRRKK +11 243 206
CysII–IV GIINTLQKYYSRVRGGRCAVLSSLPKEEQIGKCSTRGRKSSRRKK +11 373 567
CysIII–VI GIINTLQKYYSRVRGGRSAVLSCLPKEEQIGKSSTRGRKSCRRKK +11 198 292
N-term truncate GIINTLQKYYSRVRGGRSAV +4 NBc 744
C-term truncate LSSLPKEEQIGKSSTRGRKSSRRKK +7 NB NB
Middle truncate RGGRSAVLSSLPKEEQIG +1 NB NB
K30A GIINTLQAYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK +10 75 79
Y32A GIINTLQKYACRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK +11 55 135
R58A GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTAGRKCCRRKK +10 81 117
R60A GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGAKCCRRKK +10 38 106
E49A GIINTLQKYYCRVRGGRCAVLSCLPKAEQIGKCSTRGRKCCRRKK +12 146 222
R58A, R60A GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTAGAKCCRRKK +9 48 131
R64A, K66A GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCARAK +9 99 178
R65A, K67A GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRAKA +9 45 83
Patch 1 Mutants
Neut 1d GIINTLQQYYCQVRGGRCAVLSCLPKEEQIGQCSTQGQQCCRRKK +5 >5000 923
Neut 1 Cys/ Ser GIINTLQQYYSQVRGGRSAVLSSLPKEEQIGQSSTQGQQSSRRKK +5 NB NB
Neut 1a GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGQCSTQGQQCCRRKK +7 189 105
Neut 1b GIINTLQQYYCQVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK +9 216 109
Patch 2 Mutants
Neut 2d GIINTLQKYYCRVQGGQCAVLSCLPQEEQIGKCSTRGRKCCQQQQ +4 422 1568
Neut 2 Cys/ Ser GIINTLQKYYSRVQGGQSAVLSSLPQEEQIGKSSTRGRKSSQQQQ +4 NB NB
Neut 2a GIINTLQKYYCRVQGGQCAVLSCLPQEEQIGKCSTRGRKCCRRKK +8 137 147
Neut 2b GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCQQQQ +7 193 254
Neut 1+2 GIINTLQQYYCQVQGGQCAVLSCLPQEEQIGQCSTQGQQCCQQQQ 2 NB NB
aAll displacement binding experiments were performed using Eu-NDP-MSH as a competitor. Ki values (in nM) were calculated by fitting the data to a
sigmoidal, dose-response curve with variable slope.
bSee also Figure S2.
cNB, no Binding.
dSee also Figure S4.
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Binding Determinants of HBD3 and MC ReceptorsMutations of Positively Charged Patches Disrupt
Receptor Binding
Given that none of the individual aromatic, charged, or
conserved HBD3 residues is essential for MCR binding, we
investigated a potential requirement for additional binding
determinants based on regional physiochemical properties.
Inspection of the NMR structure of HBD3 shows an asymmetric
distribution of positively charged residues grouped into two
patches (Figure 1B). One patch is primarily located on the central
loop of the folded peptide (patch 1, represented by 6 residues)
while the other larger patch is found on the opposite side, local-
ized on the C-terminal tail (patch 2, represented by 7 residues).
We confirmed this arrangement of positive charges and disulfide
bond connectivity by solving the structure of an ‘‘in-house’’
HBD3 preparation. The 20 best structures from our CYANA
calculation ranked according to target function, which were all
below 10 A˚2, possessed a backbone rmsd of 0.38 A˚ between
residues 33 and 66 and were consistent with the known native
fold of HBD3 (Figure S3; Table S1).788 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 ElsevierThe presence and arrangement of the positively charged
patches on the surface of HBD3 suggests the possibility that
HBD3-melanocortin receptor binding is mediated by electro-
static interaction domains. To test this hypothesis, we measured
melanocortin receptor affinity for three charge neutral HBD3
variants, for which all charged residues from patch 1 (HBD3-
Neut1), patch 2 (HBD3-Neut2), or both patch 1 and 2 (HBD3-
Neut1+2) were substituted with glutamine residues (Table 2;
Figure S4). To ensure that these more extensively modified
HBD3 variants were folded into the native defensin conforma-
tion, we synthesized them using a full orthogonal cysteine pro-
tection scheme that allowed sequential formation of individual
disulfide bonds. After the multistep folding process was com-
plete, we confirmed by analytical HPLC and mass spectrometry
that we obtained one fully folded conformer for each variant.
Additionally, we synthesized native HBD3 using the same
orthogonal folding scheme, producing one final conformer,
which had identical MCR affinity constants and analytical
HPLC retention time as HBD3 folded by conventional oxidation.Ltd All rights reserved
Figure 3. Competitive Binding Assays with
MC1R and MC4R
Subset of competition binding assay curves for
synthetic HBD3 variants at either MC1R (A and B)
or MC4R (C and D). The logarithm of competing
ligand concentration is plotted on the abscissa
while the amount of Eu-NDP-MSH bound,
measured as relative fluorescence, is plotted on
the ordinate. See also Figure S1.
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Binding Determinants of HBD3 and MC ReceptorsSubstituting both charged patches simultaneously (HBD3-
Neut1+2) completely eliminated binding at both MC1R and
MC4R. When we independently substituted either patch 1 or
patch 2, however, we observed receptor specific differences in
binding affinity.
At MC1R, elimination of patch 1 was sufficient to severely
impair binding (HBD3-Neut1 Ki > 5 mM) whereas elimination of
patch 2 reduced binding but did not eliminate it completely
(HBD3-Neut2 Ki = 422 nM). However, affinity for MC1R was
completely lost by the HBD3-Neut2 peptide when we disrupted
its structure through elimination of disulfide bonding (HBD3-
Neut2-Cys-Ser; Table 2). In contrast, elimination of patch 1
had a significant effect on MC4R binding but did not entirely
eliminate it (HBD3 Ki = 110 nM; HBD3-Neut1 Ki = 923 nM).
Eliminating patch 2 reduced affinity for MC4R by nearly 15-fold
but did not abolish it (HBD3 Ki = 110 nM; HBD3-Neut2 Ki =
1568 nM). However, affinity for MC4R was completely lost for
either patch variant by disruption of disulfide bonding (HBD3-
Neut1-CysSer and HBD3-Neut2-CysSer; Table 2). Thus, the
positively charged surface patches of HBD3 contribute both to
receptor binding, and to binding specificity.
To interrogate the functional importance of smaller charge
clusters within each positively charged patch, we synthesized
four additional peptides: HBD3-Neut1a and HBD3-Neut1b
eliminated four and two charged residues, respectively, within
patch 1 and HB3-Neut2a and HBD3-Neut2b eliminated three
and four charged residues, respectively, within patch 2. None
of these alterations completely disrupted MC1R or MC4R bind-
ing and instead yielded a range of affinities that does not point toChemistry & Biology 20, 784–795, June 20, 2013a critical role for any single charge cluster
(Table 2). However, plotting receptor
affinity as a function of charge for all 14
variants with intact disulfide bonds
reveals a strong trend (Figure 4), which
highlights the importance of charge as a
binding determinant and suggests that
regional charge patches rather than
specific side chains mediate receptor
binding.
Regional Electrostatic Interactions:
Informatic Analysis
As described further below, we propose
that the manner in which b-defensins
bind melanocortin receptors is funda-
mentally distinct from that of ‘‘classical’’
melanocortin ligands (such as a-MSH
andASIP or AgRP), and, instead, is based
on regional electrostatic interactionsbetween positively charged patches on the surface of the ligand
with negatively charged regions on the surface of the receptor.
Previous structure-function studies of MC1R and MC4R identi-
fied several critical acidic residues found grouped together that
are essential for NDP-MSH and ASIP binding (Haskell-Luevano
et al., 2001; Yang et al., 1997). However, MC1R and MC4R
structural models also reveal several negatively charged resi-
dues on the extracellular surface of each receptor besides those
comprising the ligand binding pocket.
We used the Adaptive Poisson-Boltzmann Solver (Baker et al.,
2001) to model potential electrostatic interactions between
HBD3 or ASIP and melanocortin receptors, which revealed a
striking charge complementarity between the peptide ligands
and each receptor (Figure 5). HBD3 exhibits a positive potential
distributed almost entirely over its solvent-exposed surface,
whereas ASIP shows positive potential specifically on the loop
portion known to interact with theMCRbinding pocket (Figure 5A
and 5B). Both receptors exhibit a large negative surface potential
owing to the preponderance of acidic residues (Figure 5C and
5D), which overlaps with but is not restricted to the critical resi-
dues of the melanocortin binding pocket. We also compared
the charged distribution of melanocortin receptor segments
(the predicted transmembrane helices, extracellular, and intra-
cellular regions) with those of all known GPCRs in the human
genome. Remarkably, the melanocortin receptors possessed
among the greatest numbers of acidic residues in their exoseg-
ments: MC4R, with a 8 net charge (five Asp, three Glu), was
among the top 3% of most negatively charged GPCR exoseg-
ments and MC1R, with a 6 net charge (four Asp, four Glu,ª2013 Elsevier Ltd All rights reserved 789
Figure 4. Correlation between Overall Charge of HBD3 Variants and
MCR Binding Affinity
Peptide charge (x axis) is plotted against the log of the measured binding
affinity (Ki) at MC1R (black diamonds) and MC4R (open black squares).
Peptides lacking some or all disulfide connections were omitted, and low-
affinity HBD3 variants (with Ki values outside the detectable range of our assay)
were set to Ki = 10 mM.
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Binding Determinants of HBD3 and MC Receptorsone Lys, one Arg), was among the top 10% (Figure S5). Together
with the experimental results, observations from receptor-ligand
modeling and comparative GPCR analysis support a model
whereby HBD3 can competitively prevent binding of other
melanocortin ligands via diffuse electrostatic interactions with
receptor exosegments, without affecting the melanocortin
binding pocket or receptor conformation.
DISCUSSION
Melanocortin receptor agonists such as a-MSH are evolution-
arily unrelated to inverse agonists such as ASIP and AGRP but
both have a common structural feature: a short linear motif
(HFRW in a-MSH and RFF in ASIP and AGRP) comprised of
cationic and aromatic side chains that serves as a point of
receptor interaction. Both motifs are found on exposed loops
extending from the ligand core that interact with corresponding
acidic and aromatic residues found on the extracellular
receptor-binding surface (Chen et al., 2007; Hruby et al., 1987;
Kiefer et al., 1998; Yang et al., 2000b). Mutation of these linear
motifs (for instance, RFF / AFF in ASIP or AGRP) severely
reduces receptor affinity and ligand efficacy, thereby defining a
precise and specific interaction with the receptor-binding pocket
(Bolin et al., 1999; Kiefer et al., 1998).
HBD3 (and other b-defensins) often exhibit function away
from the cell surface, share no sequence similarity with previ-
ously characterized melanocortin receptor ligands, and our
structure-function analysis indicates that the mechanism of
HBD3 binding is also different. In contrast to ASIP and
AgRP, HBD3 binding depends primarily on two positively790 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 Elseviercharged patches located distally from each other on the
protein scaffold. While HBD3 charge alone confers MCR
binding affinity, the degree of binding is clearly enhanced by
the compact HBD3 fold, stabilized by its unique network of
disulfide bonds.
Additional biophysical and pharmacologic studies will be
necessary to rigorously test our proposed model of HBD3-
MCR binding, but we note that physiologically significant
protein-protein binding mediated largely by regional electro-
static interactions is not without precedent (Sinha and Smith-
Gill, 2002). Complementary patches of charged residues
facilitate subpicomolar binding (Kd1014 M) between a ribonu-
clease and an inhibitor protein of the Barnase-Barstar complex
(Buckle et al., 1994). Multiple studies on this pair, including
mutational analysis and electrostatic modeling of interaction
surfaces, indicate the importance of large groupings of positive
residues on Barnase and corresponding acidic as well as
nonpolar residues on its inhibitor, Barstar (Hartley, 1993;
Schreiber and Fersht, 1993). In addition, the metal-ion Zn2+ is
also capable of acting as a direct agonist for the MC1R and
MC4R (Holst et al., 2002). This interaction is most likely depen-
dent on acidic residues in and around the receptor-binding
pocket, which may also be the key residues involved in the
electrostatically driven HBD3-MCR interaction.
Biophysical differences in the way that MCR interacts with
HBD3 compared to Asip, Agrp, or a-MSH may help to explain
how HBD3 can block either a stimulatory (a-MSH) or an
inhibitory (Asip, Agrp) ligand. Inverse agonists are thought to
act by stabilizing the inactive conformation of seven transem-
brane domain receptors, i.e., one that has reduced affinity for
the Ga subunit; our results suggest that HBD3 has no effect
on the relative balance between active and inactive conforma-
tions, but causes the melanocortin binding pocket to be less
accessible to either stimulatory or inhibitory ligands. This
perspective can also explain the apparent paradox between
our initial description of b-defensin 3 as a peptide whose
effects mimicked that of a melanocortin agonist (Candille
et al., 2007), and that of Swope et al. (Swope et al., 2012),
who refer to HBD3 as an a-MSH antagonist. In vivo (in dogs
or in transgenic mice), melanocortin peptides derived from
POMC have no detectable effect on pigmentation (Slominski
et al., 2005), and the effects of b-defensin 3 are brought about
by inhibition of Asip. But HBD3 can also block the effect of
exogenous a-MSH added to cultured melanocytes (Swope
et al., 2012). Thus, the functional outcome of an HBD3-MCR
interaction with regard to whether signaling is promoted or
inhibited will depend on the specific physiologic context and
the relative balance between agonist and inverse agonist
(Figure 6).
The perspective of HBD3 as a type of ligand that interacts with
melanocortin receptors in a way that is fundamentally different
from that of a-MSH, Asip, or Agrp can also help to account for
the observations of Beaumont et al. (2012), since the behavior
of a ligand as partial agonist in heterologous cells could be influ-
enced by the cell type and assay conditions, including receptor
number, local accessibility of different G proteins, and presence
of allosteric modulators (Low, 2011). In our work, neither
CBD103 nor HBD3 affected cAMP levels in cultured mouse
melanocytes; similarly, Swope et al. (2012) observed no effectLtd All rights reserved
Figure 5. Electrostatic Potential of Melano-
cortin System Ligands and Receptors
Positive potential is displayed in blue, negative
potential is displayed in red, and neutral potential
displayed in white. (A) HBD3 (PDB ID: 1KJ6); (B)
ASIP (PDB ID: 1Y7K); (C) side and top (extracel-
lular) view of MC1R structural model highlighting
the purported ligand binding pocket; (D) side and
top (extracellular) view of MC4R structural
model (PDB ID: 2IQV). Receptor models were
obtained from http://mosberglab.phar.umich.edu/
resources/ (Chai et al., 2005; Pogozheva et al.,
2005). PDB files were prepared for electrostatic
calculations using the PDB2PQR webserver with
an AMBER force field (Dolinsky et al., 2007).
Electrostatic calculations were performed with the
Adaptive-Poisson Boltzmann Solver and visual-
ized using PyMol (Baker et al., 2001). Electrostatic
potentials were displayed on the solvent acces-
sible surface using a 3 to +3 range (units of
kbT/ec). No ligand binding orientation is implied by
the display of HBD3 or ASIP relative to the
melanocortin receptors. See also Figure S5.
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Notably, the preparation and source of HBD3 for all of these
studies is the same.
It is also important to note that our studies of HBD3 and the
MC4R are motivated by the opportunity to examine what can
happen in an in vivo pharmacologic paradigm, not what normally
happens during physiologic regulation of MC4R signaling. Some
b-defensins have been reported to be expressed in the rat brain
(Froy et al., 2005), but additional studies will be necessary to
explore the extent to which b-defensinsmight normally modulate
CNS physiology. By contrast, a physiologic (and/or pathophysi-
ologic) HBD3-MC1R interaction is better grounded, since HBD3
is expressed at very high levels by keratinocytes from psoriatic
skin (Harder et al., 2001).
Finally, our model for HBD3-MCR binding may also help to
explain the promiscuity of b-defensin action at other GPCRs. In
particular, the C-C chemokine receptor-2 (CCR2), which alsoChemistry & Biology 20, 784–795, June 20, 2013interacts with HBD3, has an electrostatic
distribution similar to MCRs and binds to
its native ligand monocyte chemotactic
protein-1 (MCP1) primarily through the
interaction of negatively charged resi-
dues on CCR2 and positively charged
clusters on MCP1 (Hemmerich et al.,
1999; Ro¨hrl et al., 2010). Similarly, the
interaction between HBD1 and C-C
chemokine receptor-6 is mediated by a
spatially diffuse set of residues (more
than half of which are positively charged)
on the HBD1 surface. (Pazgier et al.,
2007).
From a general perspective, acquisi-
tion of charge clusters by soluble pep-
tides could drive ligand promiscuity,
while acquisition of charge clusters within
GPCR exoloops could drive receptor pro-miscuity. The HBD3-MCR interaction was originally recognized
via a phenotype-driven approach, but the model described
here suggests a route for identifying analogous interactions
based on a sequence-driven approach.
SIGNIFICANCE
An unusual feature of melanocortin receptors is their
physiologic modulation in opposite directions by endoge-
nous agonists (i.e., a-MSH) and inverse agonists (i.e.,
ASIP and AgRP). Identification of HBD3 as a third type of
melanocortin receptor ligand adds an additional layer of
complexity and the ability to dampen receptor signaling
regardless of its direction. Our biochemical studies uncover
a distinct mechanism for MCR binding and regulation
that may help in drug design and in the identification of
additional GPCR ligands.ª2013 Elsevier Ltd All rights reserved 791
Figure 6. Modulation of Melanocortin
Receptor Signaling by HBD3
Because MC1R and MC4R have both stimulatory
and inhibitory ligands, the effects of a neutral
antagonist are context dependent. The schemes
on the left show the response of the indicated
ligand; those on the right show how the response
is altered by HBD3, which restores basal cAMP
levels.
(A) In mammalian skin, the primary ligand for
MC1R is Agouti protein (ASIP; there is very little
a-MSH); consequently, b-defensin 3 promotes
MC1R signaling by inhibiting inverse agonism.
(B) In cultured melanocytes stimulated by exoge-
nous a-MSH, HBD3 inhibits MC1R signaling.
(C) In the brain, HBD3 can either promote or
inhibit MC4R signaling depending on the balance
between inverse agonist (Agrp) and agonist
(a-MSH, not shown).
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Cyclic-AMP and b-Arrestin Studies
Melan-a cells (Bennett et al., 1987) were grown in RPMI supplemented with
200 nM TPA at 37C and 10% CO2. For cyclic-AMP (cAMP) assays, the cells
were plated onto 96-well half-area plates (Corning #3885) at a density of
20,000 cells/well and grown for 24 hr. After a single wash with phosphate buff-
ered saline (PBS [pH 7.4]), peptides (diluted in PBS [pH7.4] containing 0.2%
BSA and 0.5 mM IBMX) were added and the plate was incubated at 37C and
10% CO2 for 40 min. cAMP levels were measured using the Hithunter cAMP
XS kit (DiscoveRx) with a Centro LB 960 plate reader (Berthold Technologies).
The assay was performed in triplicate and analyzed using Graphpad (Prism).
b-arrestin recruitment was measured using a commercial assay system
(PathHunter, Discoverx), based on an enzyme complementation strategy
that measures MC1R specific b-arrestin recruitment in an engineered Chinese
Hamster Ovary cell line. Cells were seeded at a density of 10,000 cells/well and
grown for 48 hr in Optimized Cell Culture media (DiscoveRx). Ten microliters of
each ligand, diluted in media, was added to the cells at final concentrations
ranging from 1.0 mM to 5.7 pM (MT-II and CBD103) or from 0.1 mM to 0.57
pM (ASIP-YY). The plate was incubated for 90 min at 37C. PathFinder detec-
tion reagent (54 ml) was added to each well, and the plate was incubated for
90 min at room temperature before reading with a Centro LB 960 plate reader
(Berthold Technologies). The assay was performed in triplicate and repeated
twice for CBD103.
Experimental Animals
All study protocols were approved by the Animal Care and Use Committee at
Stanford University (transgenic mouse studies) or the University ofWashington792 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 Elsevier Ltd All rights reserved(energy balance studies) and conducted in accor-
dance with NIH guidelines for the care and use of
animals.
The transgenic mouse line, Tg.CBD103GD23, in
which the Dominant black allele of CBD103 is
expressed under regulation of a cytomegalo-
virus/bb-actin hybrid (CAGGS) promoter, has
been described previously (Candille et al., 2007;
Okabe et al., 1997). Two of the mouse strains,
C57BL/6J-Mc1re/J and C57BL/6J-Ay/J, were
originally obtained from Jackson Laboratories
and maintained in house on C57BL/6J back-
ground. Pomc mice, obtained from Yaswen
et al. (1999), were on amixed genetic background.
Tg.CBD103GD23/;Ay/ mice were recovered
from F1 crosses. Tg.CBD103GD23/;Mc1re/e
and Tg.CBD103GD23/;Pomc/ mice were re-
covered from F2 crosses in which eitherTg.CBD103GD23/;Mc1re/+ or Tg.CBD103GD23/;Pomc/+ individuals
were backcrossed to Mc1re/e or Pomc/+mice, respectively. Coat color was
recorded at weaning and genotyping performed with the appropriate primers.
(Genotyping primers available upon request.)
Energy Balance Studies
Adult male Wistar rats were housed individually in a specific pathogen-free
environment, maintained in a temperature-controlled room with a 12–12 hr
light/dark cycle and provided with ad libitum access to water and standard
laboratory chow (PMI Nutrition International) unless otherwise stated. For
the ICV injection studies, rats were first implanted with an indwelling stainless
steel cannula to the third cerebral ventricle (3V) under isoflurane anesthesia as
previously described (Schwartz et al., 1992). Buprenorphine hydrochloride
(0.3 mg/kg; Rickett Colman Pharmaceuticals) was administered at the
completion of the surgery. Rats recovered for at least seven days after surgery
while daily food intake and body weight were recorded. Cannula placement
was verified before the start of the experiment through the measurement of
a sympathetically mediated increase in plasma glucose 60 min following
3rd-icv injection of 210 mg of 5-thio-D-glucose.
Animals were habituated to regular handling and received a mock injection
prior to the commencement of experiments. To determine whether central
administration of HBD3 attenuates the refeeding response following a fast,
animals received an ICV injection of either vehicle (water) or HBD3 at a dose
of 7 mg (n = 6–7/group). Injections were administered using an injector (33
gauge) needle that extended 1 mm beyond the tip of the cannula over a period
of 60 s in a final volume of 2 ml. Food was immediately withdrawn from the
animals and replaced again 24 hr later. Food intake and body weight were
measured prior to the fast, at the completion of the fast, and at 24 hr following
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animals received an ICV pretreatment injection of either vehicle or HBD3 1 hr
prior to ICV administration of AgRP (0.01nmol) or its vehicle to create three
groups: (1) Veh-Veh, (2) Veh-AgRP, and (3) HBD3-AgRP (n = 8–10/group).
Body weight gain was measured over a 5 day period following injections.
Peptide Synthesis
Peptides were produced on either an Applied Biosystems 433A peptide syn-
thesizer or a CEM Liberty1 microwave peptide synthesizer using standard
Fmoc chemistry. Amino acids were purchased from NovaBiochem and were
assembled on Rink-amide-MBHA resin. For peptides produced on the Applied
Biosystems 433A synthesizer, preactivated Fmoc-Cys(Trt)-OPfp was used to
avoid enantiomerization. HBTU was purchased from Advanced Chemtech; all
other reagents were purchased from Sigma-Aldrich. Fmoc protecting groups
were removed using a 1% DBU/HMI mixture in DMF while four equivalents of
an amino acid/HBTU/DIEAmixture was used for coupling (except preactivated
Fmoc-Cys(Trt)-Opfp, which was only coupled in DMF solution). For peptides
produced on the CEM Liberty1 synthesizer, Fmoc protecting groups were
removed using 20% piperidine with 0.1 M HOBt in DMF. Amino acids were
coupled using 5 molar equivalents of Diisopropylcarbodiimide (DIC) and 10
molar equivalents of hydroxybenzotriazole (HOBt) in DMF. Cleavage of all
peptides was performed in a TFA/TIS/EDT/Phenol (90:4:4:2) solution for
90 min. Standard oxidative folding was achieved by dissolving peptides to a
concentration of 0.1 mg/mL in folding buffer (0.5–1.0 M GuHCl, 0.1M Tris,
1 mM GSH, 0.1 mM GSSG [pH 8.5]) and stirring for 48 hr. Folding was moni-
tored by HPLC, which, in each case, revealed one major species that was
used in subsequent experiments. For peptides produced with full-orthogonal
cysteine protection, disulfides were formed according to previously published
protocols (Schulz et al., 2005). Briefly, peptides were synthesized as outlined
above except for the cysteine precursor, in which we utilized three different
kinds of side-chain protecting groups. Cysteines 1 and 5 were protected
with the standard Trityl protecting group, which is removed during the TFA
cleavage step. Cysteines 2 and 4 were protected using the acetamidomethyl
(Acm) protecting group, and cysteines 3 and 6 were protected with the
tert-butyl protecting group. The first disulfide (CysI-CysV) was formed using
our standard oxidative folding buffer. The second disulfide (CysII-CysIV) was
formed using a solution of molecular iodine in glacial acetic acid that simulta-
neously removes the Acm protecting group and oxidizes the disulfide. The
third and final disulfide (CysIII-CysVI) was formed using a DMSO/Anisole
mixture in neat TFA, which simultaneously removes the tert-butyl protecting
group and oxidizes the disulfide. The folded products were purified by C18
column HPLC and identified as fully oxidized peptides by mass spectrometry.
Quantitative concentrations were determined with amino acid analysis at the
molecular structure facility at UC Davis.
NMR Spectroscopy and Structure Calculations
NMR samples were prepared in pH 5.0 buffer consisting of 10% D20, 50 mM
CD3COOD, 0.1% w/v NaAzide, 200 mM TMSP, and NaOD for pH adjustment.
Susceptibility-matched NMR tubes (Shigemi) were used to accommodate the
small sample volumes (350 mls), which resulted inworking peptide concentra-
tions between 1and 2mM. The NOESY, TOCSY, and DQF-COSY spectra were
acquired on a 900 MHz Bruker Avance II NMR spectrometer equipped with a
TCI cryoprobe (HCN) housed in theUCBerkeleyNMR facility. TheHSQCexper-
iments were performed on a 600 MHz Varian Unity+ spectrometer equipped
with a cryoprobe at UCSC. Water suppression for NOESY, TOCSY, and DQF-
COSY spectra was achieved using the WATERGATE sequence, while HSQC
water suppression utilized standard TN sequences. The NOESY and TOCSY
spectra were obtained at 25C with 2048 complex points in the t2 dimension,
400 t1 increments, and a spectral width of 10,901Hz. The DQF-COSY spectra
were obtained with 8192 complex points in the t2 dimension and 256 t1 incre-
ments. The HSQC spectra were acquired with 1024 complex points in the t2
dimension, 128 t1 increments, and a spectral width of 8426 Hz. All data was
processed using the NMRPipe software package (Delaglio et al., 1995).
Peak assignment and integration was performed manually using SPARKY
after which peak and chemical shift lists were converted to XEASY format
for use in CYANA structure calculations (Goddard and Kneller, 2008). Auto-
mated NOE peak assignment and structure calculations were carried out using
CYANA 2.1 on a Macintosh G4 (OS version 10.5) and an Intel Core2 QuadChemistry & Biology 20,running Linux openSUSE 11.1 (Gu¨ntert, 2004). Data inputs included a list of
chemical shifts, an integrated NOE peak list, dihedral angle constraint files,
and disulfide bond constraints in the form of pseudo-NOE upper-distance
limits between cysteine pairs. Two dihedral angle constraint files were gener-
ated separately prior to use in the structure calculations. We used 30 3JHa-HN
coupling constants obtained from the DQF-COSY spectra to generate one
dihedral angle restraint file using the macro GRIDSEARCH in CYANA. A
second dihedral angle constraint file was generated using the output from
the online program PREDITOR which uses backbone alpha and amide
chemical shift values and the primary sequence as input data to predict 4,
c, c1, and u torsion angles (Berjanskii et al., 2006). Calculations utilized
1000 seed structures with 10,000 simulated annealing steps using torsion
angle dynamics, and the resulting best 20 structures sorted by target function
were employed in our structure-function analysis. We performed energy mini-
mization with different disulfide linkages and found that the consensus disul-
fide pattern gave the lowest target function value. Molecular graphics images
were produced using either the UCSF Chimera package or the Pymol Molec-
ular Graphics System, Version 1.3, Schro¨dinger (Pettersen et al., 2004).
Competitive Binding Assays
All receptor-ligand binding assays were performed using the DELFIA lantha-
nide-based detection system on intact HEK 293T cells transiently transfected
with MCR expression constructs. The human MC1R and MC4R constructs
were generously provided by Dr. Ying- Kui Yang, Department of Pediatric
Surgery, University of Alabama, Birmingham. For binding assays, a 10 cm
dish of 293T cells was transfected with 10 mg of a melanocortin receptor
expression construct using calcium phosphate, with transfection efficiency
monitored by parallel transfection with a GFP-tagged MC4R construct. After
6–12 hr, the media was replaced. After 20 hr, the cells were dissociated
from the plate with an enzyme-free cell dissociation buffer (Life Technologies),
washed once with PBS, resuspended in L*R binding buffer (PerkinElmer), and
then plated on a 96-well Acrowell filtration plate (Pall). The Europium-labeled
NDP-MSHwas obtained two different ways: a custom order fromPerkin-Elmer
and an in-house preparation. For the in-house preparation, NDP-MSH was
synthesized with the addition of a C-terminal cysteine, which was subse-
quently labeled with the Perkin-Elmer DELFIA Eu-N1-iodoacetamide chelate
labeling reagent using their recommended protocol (catalog number AD0002).
Dissociation constants (Kd) for both Eu-NDP-MSH preparations at MC1R
and MC4R were measured in saturation binding assays, with nonspecific
Eu-NDP-MSH binding determined by blocking with 1.25 mM of unlabeled
NDP-MSH.
For displacement binding experiments, Eu-NDP-MSH (ranging from 0.5 mM
to 2.5 mM across experiments) was added together with a 3-fold serial dilution
of HBD3 peptides (from 9.03 106 M to 4.63 1010 M). After a 2 hr incubation
at 37C, plates were washed three times with ice-cold DELFIA wash buffer
(PerkinElmer) and the europium chelate was then dissociated by
adding150 ml of DELFIA enhancement solution (PerkinElmer) to each well.
Plates were then incubated at room temperature for at least 45 min and
time-resolved fluorescence measured using a FluoStar Optima plate reader
(BMG Labtech). The conditions for displacement binding with regard to cell
density (10,000–70,000 cells/well) and Eu-NDP-MSH concentration (ranging
from 0.5 mM to 2.5 mM across experiments) were based on prior studies
(Candille et al., 2007), with adjustments made for variation among different
preparations of Eu-NDP-MSH. The time and temperature used for the binding
assay were based on prior experiments and recommendations from
PerkinElmer. Displacement binding data were analyzed using either Graphpad
(Prism) or Kaleidograph (Synergy Software, Version 3.6.4). All affinity measure-
ments in Table 2 are representative of three independent experiments
performed in duplicate.
SUPPLEMENTAL INFORMATION
Supplemental Information including five figures and one table can be found
with this article online at http://dx.doi.org/10.1016/j.chembiol.2013.04.015.
ACKNOWLEDGMENTS
This work was supported by NIH grant DK064265 (GM).784–795, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 793
Chemistry & Biology
Binding Determinants of HBD3 and MC ReceptorsReceived: June 30, 2011
Revised: April 24, 2013
Accepted: April 26, 2013
Published: June 20, 2013
REFERENCES
Baker, N.A., Sept, D., Joseph, S., Holst, M.J., and McCammon, J.A. (2001).
Electrostatics of nanosystems: application to microtubules and the ribosome.
Proc. Natl. Acad. Sci. USA 98, 10037–10041.
Barsh, G., Gunn, T., He, L., Schlossman, S., and Duke-Cohan, J. (2000).
Biochemical and genetic studies of pigment-type switching. Pigment Cell
Res. 13 (Suppl 8 ), 48–53.
Bauer, F., Schweimer, K., Kluver, E., Conejo-Garcia, J.R., Forssmann, W.G.,
Rosch, P., Adermann, K., and Sticht, H. (2001). Structure determination of
human and murine beta-defensins reveals structural conservation in the
absence of significant sequence similarity. Prot. Sci. 10, 2470–2479.
Beaumont, K.A., Smit, D.J., Liu, Y.Y., Chai, E., Patel, M.P., Millhauser, G.L.,
Smith, J.J., Alewood, P.F., and Sturm, R.A. (2012). Melanocortin-1 receptor-
mediated signalling pathways activated by NDP-MSH and HBD3 ligands.
Pigment Cell Melanoma Res. 25, 370–374.
Bennett, D.C., Cooper, P.J., and Hart, I.R. (1987). A line of non-tumorigenic
mouse melanocytes, syngeneic with the B16 melanoma and requiring a
tumour promoter for growth. Int. J. Cancer 39, 414–418.
Berjanskii, M.V., Neal, S., and Wishart, D.S. (2006). PREDITOR: a web server
for predicting protein torsion angle restraints. Nucleic Acids Res. 34(Web
Server issue), W63–W69.
Bolin, K.A., Anderson, D.J., Trulson, J.A., Thompson, D.A., Wilken, J., Kent,
S.B., Gantz, I., and Millhauser, G.L. (1999). NMR structure of a minimized
human agouti related protein prepared by total chemical synthesis. FEBS
Lett. 451, 125–131.
Boniotto, M., Antcheva, N., Zelezetsky, I., Tossi, A., Palumbo, V., Verga
Falzacappa, M.V., Sgubin, S., Braida, L., Amoroso, A., and Crovella, S.
(2003). A study of host defence peptide beta-defensin 3 in primates.
Biochem. J. 374, 707–714.
Buckle, A.M., Schreiber, G., and Fersht, A.R. (1994). Protein-protein recogni-
tion: crystal structural analysis of a barnase-barstar complex at 2.0-A resolu-
tion. Biochemistry 33, 8878–8889.
Candille, S.I., Kaelin, C.B., Cattanach, B.M., Yu, B., Thompson, D.A., Nix,
M.A., Kerns, J.A., Schmutz, S.M., Millhauser, G.L., and Barsh, G.S. (2007). A
-defensin mutation causes black coat color in domestic dogs. Science 318,
1418–1423.
Chai, B.X., Pogozheva, I.D., Lai, Y.M., Li, J.Y., Neubig, R.R., Mosberg, H.I., and
Gantz, I. (2005). Receptor-antagonist interactions in the complexes of agouti
and agouti-related protein with human melanocortin 1 and 4 receptors.
Biochemistry 44, 3418–3431.
Chen, M., Cai, M., Aprahamian, C.J., Georgeson, K.E., Hruby, V., Harmon,
C.M., and Yang, Y. (2007). Contribution of the conserved amino acids of the
melanocortin-4 receptor in [corrected] [Nle4,D-Phe7]-alpha-melanocyte-
stimulating [corrected] hormone binding and signaling. J. Biol. Chem. 282,
21712–21719.
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995).
NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J. Biomol. NMR 6, 277–293.
Dolinsky, T.J., Czodrowski, P., Li, H., Nielsen, J.E., Jensen, J.H., Klebe, G.,
and Baker, N.A. (2007). PDB2PQR: expanding and upgrading automated
preparation of biomolecular structures for molecular simulations. Nucleic
Acids Res. 35(Web Server issue), W522–W525.
Ferguson, S.S., Downey, W.E., 3rd, Colapietro, A.M., Barak, L.S., Me´nard, L.,
and Caron, M.G. (1996). Role of beta-arrestin in mediating agonist-promoted
G protein-coupled receptor internalization. Science 271, 363–366.
Froy, O., Hananel, A., Chapnik, N., and Madar, Z. (2005). Differential expres-
sion of rat beta-defensins. IUBMB Life 57, 41–43.
Goddard, T.D., and Kneller, D.G. (2008). SPARKY 3 (San Francisco, CA:
University of California, San Francisco).794 Chemistry & Biology 20, 784–795, June 20, 2013 ª2013 ElsevierGu¨ntert, P. (2004). Automated NMR structure calculation with CYANA.
Methods Mol. Biol. 278, 353–378.
Harder, J., Bartels, J., Christophers, E., and Schroder, J.M. (2001). Isolation
and characterization of human beta -defensin-3, a novel human inducible pep-
tide antibiotic. J. Biol. Chem. 276, 5707–5713.
Hartley, R.W. (1993). Directed mutagenesis and barnase-barstar recognition.
Biochemistry 32, 5978–5984.
Haskell-Luevano, C., Cone, R.D.,Monck, E.K., andWan, Y.P. (2001). Structure
activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identi-
fication of agouti-related protein (AGRP), melanocortin agonist and synthetic
peptide antagonist interaction determinants. Biochemistry 40, 6164–6179.
Hemmerich, S., Paavola, C., Bloom, A., Bhakta, S., Freedman, R., Grunberger,
D., Krstenansky, J., Lee, S., McCarley, D., Mulkins, M., et al. (1999).
Identification of residues in the monocyte chemotactic protein-1 that contact
the MCP-1 receptor, CCR2. Biochemistry 38, 13013–13025.
Holst, B., Elling, C.E., and Schwartz, T.W. (2002). Metal ion-mediated agonism
and agonist enhancement in melanocortin MC1 and MC4 receptors. J. Biol.
Chem. 277, 47662–47670.
Hoover, D.M., Chertov, O., and Lubkowski, J. (2001). The structure of human
beta-defensin-1: new insights into structural properties of beta-defensins.
J. Biol. Chem. 276, 39021–39026.
Hoover, D.M., Rajashankar, K.R., Blumenthal, R., Puri, A., Oppenheim, J.J.,
Chertov, O., and Lubkowski, J. (2000). The structure of human beta-defen-
sin-2 shows evidence of higher order oligomerization. J. Biol. Chem. 275,
32911–32918.
Hruby, V.J., Wilkes, B.C., Hadley, M.E., Al-Obeidi, F., Sawyer, T.K., Staples,
D.J., de Vaux, A.E., Dym, O., Castrucci, A.M., Hintz, M.F., et al. (1987).
alpha-Melanotropin: the minimal active sequence in the frog skin bioassay.
J. Med. Chem. 30, 2126–2130.
Kiefer, L.L., Veal, J.M., Mountjoy, K.G., and Wilkison, W.O. (1998).
Melanocortin receptor binding determinants in the agouti protein.
Biochemistry 37, 991–997.
Klu¨ver, E., Schulz-Maronde, S., Scheid, S., Meyer, B., Forssmann, W.G., and
Adermann, K. (2005). Structure-activity relation of human beta-defensin 3:
influence of disulfide bonds and cysteine substitution on antimicrobial activity
and cytotoxicity. Biochemistry 44, 9804–9816.
Lehrer, R.I. (2004). Primate defensins. Nat. Rev. Microbiol. 2, 727–738.
Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G., and Lefkowitz, R.J. (1990).
beta-Arrestin: a protein that regulates beta-adrenergic receptor function.
Science 248, 1547–1550.
Low, M.J. (2011). Agnostic about in vivo inverse agonism of agouti-related
peptide. Endocrinology 152, 1731–1733.
Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T., and Nishimune, Y. (1997).
‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 407, 313–319.
Ollmann, M.M., and Barsh, G.S. (1999). Down-regulation of melanocortin
receptor signaling mediated by the amino terminus of Agouti protein in
Xenopus melanophores. J. Biol. Chem. 274, 15837–15846.
Patil, A.A., Cai, Y., Sang, Y., Blecha, F., and Zhang, G. (2005). Cross-species
analysis of the mammalian beta-defensin gene family: presence of syntenic
gene clusters and preferential expression in the male reproductive tract.
Physiol. Genomics 23, 5–17.
Pazgier, M., Hoover, D.M., Yang, D., Lu, W., and Lubkowski, J. (2006). Human
beta-defensins. Cell. Mol. Life Sci. 63, 1294–1313.
Pazgier, M., Prahl, A., Hoover, D.M., and Lubkowski, J. (2007). Studies of the
biological properties of human beta-defensin 1. J. Biol. Chem. 282, 1819–
1829.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M.,
Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera—a visualization system
for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.
Pogozheva, I.D., Chai, B.X., Lomize, A.L., Fong, T.M., Weinberg, D.H.,
Nargund, R.P., Mulholland, M.W., Gantz, I., and Mosberg, H.I. (2005).
Interactions of human melanocortin 4 receptor with nonpeptide and peptide
agonists. Biochemistry 44, 11329–11341.Ltd All rights reserved
Chemistry & Biology
Binding Determinants of HBD3 and MC ReceptorsRo¨hrl, J., Yang, D., Oppenheim, J.J., and Hehlgans, T. (2010). Human beta-de-
fensin 2 and 3 and their mouse orthologs induce chemotaxis through interac-
tion with CCR2. J. Immunol. 184, 6688–6694.
Sawai, M.V., Jia, H.P., Liu, L., Aseyev, V., Wiencek, J.M., McCray, P.B., Jr.,
Ganz, T., Kearney, W.R., and Tack, B.F. (2001). The NMR structure of human
beta-defensin-2 reveals a novel a-helical segment. Biochemistry 40, 3810–
3816.
Schibli, D.J., Hunter, H.N., Aseyev, V., Starner, T.D., Wiencek, J.M., McCray,
P.B., Jr., Tack, B.F., and Vogel, H.J. (2002). The solution structures of the
human beta-defensins lead to a better understanding of the potent bacteri-
cidal activity of HBD3 against Staphylococcus aureus. J. Biol. Chem. 277,
8279–8289.
Schreiber, G., and Fersht, A.R. (1993). Interaction of barnase with its polypep-
tide inhibitor barstar studied by protein engineering. Biochemistry 32, 5145–
5150.
Schulz, A., Klu¨ver, E., Schulz-Maronde, S., and Adermann, K. (2005).
Engineering disulfide bonds of the novel human beta-defensins hBD-27 and
hBD-28: differences in disulfide formation and biological activity among hu-
man beta-defensins. Biopolymers 80, 34–49.
Schwartz, M.W., Sipols, A.J., Marks, J.L., Sanacora, G., White, J.D.,
Scheurink, A., Kahn, S.E., Baskin, D.G., Woods, S.C., Figlewicz, D.P., et al.
(1992). Inhibition of hypothalamic neuropeptide Y gene expression by insulin.
Endocrinology 130, 3608–3616.
Semple, F., MacPherson, H., Webb, S., Cox, S.L., Mallin, L.J., Tyrrell, C.,
Grimes, G.R., Semple, C.A., Nix, M.A., Millhauser, G.L., and Dorin, J.R.
(2011). Human b-defensin 3 affects the activity of pro-inflammatory pathways
associated with MyD88 and TRIF. Eur. J. Immunol. 41, 3291–3300.
Sinha, N., and Smith-Gill, S.J. (2002). Electrostatics in protein binding and
function. Curr. Protein Pept. Sci. 3, 601–614.Chemistry & Biology 20,Slominski, A., Plonka, P.M., Pisarchik, A., Smart, J.L., Tolle, V., Wortsman, J.,
and Low, M.J. (2005). Preservation of eumelanin hair pigmentation in proopio-
melanocortin-deficient mice on a nonagouti (a/a) genetic background.
Endocrinology 146, 1245–1253.
Swope, V.B., Jameson, J.A., McFarland, K.L., Supp, D.M., Miller, W.E.,
McGraw, D.W., Patel, M.A., Nix, M.A., Millhauser, G.L., Babcock, G.F., and
Abdel-Malek, Z.A. (2012). Defining MC1R regulation in human melanocytes
by its agonist a-melanocortin and antagonists agouti signaling protein and
b-defensin 3. J. Invest. Dermatol. 132, 2255–2262.
Tota, M.R., Smith, T.S., Mao, C., MacNeil, T., Mosley, R.T., Van der Ploeg,
L.H., and Fong, T.M. (1999). Molecular interaction of Agouti protein and
Agouti-related protein with human melanocortin receptors. Biochemistry 38,
897–904.
Yang, D., Chen, Q., Chertov, O., and Oppenheim, J.J. (2000a). Human neutro-
phil defensins selectively chemoattract naive T and immature dendritic cells.
J. Leukoc. Biol. 68, 9–14.
Yang, D., Chertov, O., Bykovskaia, S.N., Chen, Q., Buffo, M.J., Shogan, J.,
Anderson, M., Schro¨der, J.M., Wang, J.M., Howard, O.M., and Oppenheim,
J.J. (1999). Beta-defensins: linking innate and adaptive immunity through den-
dritic and T cell CCR6. Science 286, 525–528.
Yang, Yk., Dickinson, C., Haskell-Luevano, C., and Gantz, I. (1997). Molecular
basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with
the human melanocortin-1 receptor. J. Biol. Chem. 272, 23000–23010.
Yang, Y.K., Fong, T.M., Dickinson, C.J., Mao, C., Li, J.Y., Tota, M.R., Mosley,
R., Van Der Ploeg, L.H., andGantz, I. (2000b). Molecular determinants of ligand
binding to the human melanocortin-4 receptor. Biochemistry 39, 14900–
14911.
Yaswen, L., Diehl, N., Brennan, M.B., and Hochgeschwender, U. (1999).
Obesity in the mouse model of pro-opiomelanocortin deficiency responds to
peripheral melanocortin. Nat. Med. 5, 1066–1070.784–795, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 795
